John F DeGroot
University of California, San Francisco · 115 works · 6,899 citations · h-index 21
Top works
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
- Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
- Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
- Peripheral glutamate release in the hindpaw following low and high intensity sciatic stimulation
- Clinical trial end points for high-grade glioma: the evolving landscape
- The reorganization of μ opioid receptors in the rat dorsal horn following peripheral axotomy
- Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair
- NEURO/MEDICAL ONCOLOGY
- Clinical and prognostic features of adult patients with gangliogliomas
- Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma
- Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group
- Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
- Intermediate-Risk Meningioma: Initial Outcomes from NRG Oncology/RTOG-0539
- Opening of the Blood–Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models
- Ongoing Clinical Trials
- Profiles of brain metastases: Prioritization of therapeutic targets
- Radiation with STAT3 Blockade Triggers Dendritic Cell–T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy
- GENE-28. LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS
- NRG/RTOG 1122: A phase 2, double‐blinded, placebo‐controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma
- INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS